Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C [Yahoo! Finance]
Ardelyx, Inc. (ARDX)
Last ardelyx, inc. earnings: 3/6 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ardelyx.com/investor-relations
Company Research
Source: Yahoo! Finance
Ardelyx, Inc. Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, including pain, discomfort, and bloating, during 12 weeks of treatment WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the publication of data from its IBS-C clinical development program, “Tenapanor is associated with earlier and sustained symptom relief in IBS-C: a post hoc analysis” in Therapeutic Advances in Gastroenterology , an international, peer-reviewed, open-access journal focused on advancing clinical practice and research in digestive diseases. Tenapanor, branded as IBSRELA ® (tenapanor), is a first-in-class retainagogue that is approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with constipation (IBS-C) in adult
Show less
Read more
Impact Snapshot
Event Time:
ARDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARDX alerts
High impacting Ardelyx, Inc. news events
Weekly update
A roundup of the hottest topics
ARDX
News
- Ardelyx (ARDX) was given a new $17.00 price target by Williams Trading.MarketBeat
- Ardelyx (ARDX) had its "outperform" rating reaffirmed by Leerink Partners.MarketBeat
- Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award [Yahoo! Finance]Yahoo! Finance
- Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate AwardGlobeNewswire
- Ardelyx Touts IBSRELA's 73% Growth, Reaffirms $1B 2029 Goal and Details CIC Phase III Plan [Yahoo! Finance]Yahoo! Finance
ARDX
Earnings
- 2/19/26 - Miss
ARDX
Sec Filings
- 2/25/26 - Form 4
- 2/24/26 - Form 144
- 2/23/26 - Form 4
- ARDX's page on the SEC website